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Antiplatelet is the most commonly drug used as secondary prevention for 
Coronary Heart Disease (CHD). The aim of this study was to determine the profile of 
the use of antiplatelet related with its efficacy and side effects. Observational methods 
with cross sectional approach for 3 months follow up was used,  a descriptive analysis 
carried out at the private hospital in Surabaya.  Results from this study: aspirin 80 mg 
was the most prescribed antiplatelet in patients with the incidence of ischemic events 
9%. Higher ischemic events also seen in patients with hypertension, dyslipidemia, and 
Diabetes Mellitus. Bleeding and gastrointestinal disturbance as side effects occurred in 
4 patients who used aspirin as antiplatelet, and based for Naranjo scale can be 
concluded as possible adverse drug reaction.  
 





Data from Basic Health Research 
(RISKESDAS) in 2018 showed the 
prevalence of cardiovascular diseases in 
Indonesia , such as heart 
disease prevalence approximately 1.5%, 
8.36% hypertension, and stroke was 
10.9%. In East Java Province, the 
prevalence of heart disease patient was 
1.5%, hypertension patients were 8.01%, 
and stroke patients were 12.4%. 
One of the common therapies for the 
management of Coronary Heart Disease 
(CHD) is antiplatelet. Antiplatelet is a drug 
used to prevent platelet aggregation in the 
blood. Platelet aggregation can 
cause blood coagulation that triggers a 
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2015). Antiplatelet therapy is an important 
therapy for secondary 
prevention of coronary artery 
disease accompanied by lifestyle 
modification and controlling 
cardiovascular risk factors (Pilgrim T, 
2014). Besides being used for coronary 
artery disease therapy , antiplatelet can 
also be used in patents with PCI therapy 
(Tayeb HM et al , 2011). Antiplatelet 
drugs can protect against the incidence of 
myocardial infarction, stroke, and 
cardiovascular death in patients with a 
history of previous vascular events or risk 
factors for cardiovascular disease (Hankey 
GJ and Eikelboom JW, 2003). Oral 
antiplatelet agents for secondary 
prevention include cyclooxygenase 1 inhib
itors  namely aspirin and 
P2Y12 inhibitors that depend on 
ADP, such as clopidogrel, ticagrelor, and 
prasugrel.(Pilgrim T, 2014). 
Beyond its efficacy in CHD, 
antiplatelet also have main side effects. 
Common side effects from antiplatelets is 
bleeding which can be seen by looking at 
symptoms such as bleeding in the gums, 
nasal bleeding and bruising (Gregg D, 
2003). In addition, antiplatelet therapy also 
causes gastrointestinal bleeding, especially 
in elderly patients. Reported risk factors 
for gastrointestinal bleeding include 
advance age, female sex, major organ 
dysfunction (heart, lung, or liver), 
diabetes, hypertension, positive results 
for Helicobacter pylori infection and 
haemostatic abnormalities (Yasuda H, 
2015). The use of antiplatelet agents 
combined with anticoagulants, Non-
Steroidal Anti-Inflammatory (NSAID) can 
also increase the risk of bleeding.  Proton 
Pump Inhibitors (PPI) can be used to 
reduce the risk of gastrointestinal bleeding 
can be used together with  (Rodriguez 
LA., Et al. 2016).   
Based on the data above, research 
will be conducted on the use of antiplatelet 
to see the incidence of ischemic event and 
side effects of bleeding in outpatient 




This study was an observational 
study with a cross sectional approach 
in which variable data retrieval was carried 
out at one time at the same time by using 
descriptive analysis. 
This research was conducted in a private 
hospital in Surabaya.  
A. Population and Sample 
The population in this study were 
all outpatient coronary heart disease 
patients at cardiology polyclinic. at a 
hospital in Surabaya. Inclusion criteria for 
sample in this study were: patients were 
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antiplatelet therapy, did not have hearing 
sensory problems.  
  
B. Method of collecting data 
This research was started by 
giving  informed consent to provide 
information about what should be done to 
participate in this research, patient have 
rights to decline any data if they don’t 
want. Furthermore ,  patient data collection 
is obtained through the patient's medical 
record. The record includes name, age, 
gender, weight, height, comorbidities 
condition and drugs used. Ischemic events 
and side effects obtained from patient 
medical record and patient’s interview.  
 
C. Data analysis 
Data obtained from this study will be 
analyzed using descriptive statistical 
techniques . The results obtained in the 
form of tables , diagrams and percentages. 
 
III. RESULTS AND DISCUSSION 
Ischemic events difference can be 
seen based on antiplatelet  (Table I) , 
gender (Table II), age (Table 
III) , comorbidic conditions (Table IV). 
Incidence of side effects of antiplatelet 




Table I. Cross Tabulation Between 










aspirin 80 mg 6 (9%) 31 (45%) 37 (54%) 
clopidogrel 75 
mg 
- 14 (20%) 14 (20%) 
aspirin 80 mg + 
clopidogrel 75 
mg 
2 (3%) 12 (17%) 14 (20%) 




- 4 (6%) 4 (6%) 
Total 8 (12%) 61 (88%) 69 (100%) 
 
Based on Table I above, most 
commonly used of antiplatelet therapy 
was aspirin 80 mg from February-April 
2018 for 37 (54%) patients. 45% patients 
didn’t experienced any ischemic events 
with Aspirin 80 mg during 3 months 
follow up. Clopidogrel is used by 20% 
patients as single antiplatelet therapy. 
Based on guideline recommendations for 
Chronic Coronary Syndrome, Aspirin is 
the first line therapy for antiplatelet in 
CCS patients who didn’t get any Acute 
Coronary Syndrome or undergone PCI 
procedure. In addition there were 
4 (5%) patients who switched 80 
mg aspirin to 75 mg clopidogrel, this was 
because the patient had gastrointestinal 
complaints. The total number of 
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antiplatelet therapy (80mg  aspirin  + 75 
mg clopidogrel is 14 (20%) patients, this 
combination can reduce the incidence of 
chest pain by 12 (17%) patients .  
 
Table II. Cross Tabulation Between 














6 (9%) 31 (45%) 37 (54%) 
Male 3 (4%) 23 (33%) 26 (38%) 
women 3 (4%) 8 (12%) 11 (16%) 
clopidogrel 
75 mg 
-     
Male - 7 (10%) 7 (10%) 





2 (3%) 12 (17%) 14 (20%) 
Male 2 (3%) 11 (16%) 13 (19%) 





- 4 (6%) 4 (6%) 
women - 4 (6%) 4 (6%) 
Total 8 (12%) 61 (88%) 69 (100%) 
  
Based on table II, we can see that 
there were no difference between male and 
female in incidence of ischemic events.  
According to Ittaman SV in 2014 it was 
said that the use of aspirin was primarily 
aimed at the sex of men compared to 
women. The reasons for differences in the 
effects of aspirin therapy by sex are 
currently unknown, but evidence suggests 
that there may be some biological basis for 
these differences.  
Special characteristic for women is 
the influence of their hormonal status on 
CHD. In comparison with men of a similar 
age and postmenopausal women 
suggesting that endogenous estrogens have 
a protective effect on the development of 
CHD. Estrogen affect the atheroschlerotic 
process through a variety of mechanism. It 
has been reported to have a lowering effect 
on total cholesterol and LDL, lipoprotein, 
and homocystein levels. HDL levels are 
increased and postprandial lipid 
metabolism improved by estrogens. 
Moreover, estrogens have an acute 
vasodilatory effect on the vessel wall and 
an atheroprotective effect involving 
inhibition of smooth muscle cell 
proliferation (Lennep et al, 2002). But 
after postmenopause, the risk to suffering 
from CHD is equal between men and 
women, because of the decrease in women 
estrogen production. 
The relationship of antiplatelet 
therapy with ischemic events based on age 
can be seen in Table III. Patients aged 65-
69 years were the highest 
age using aspirin 80mg, 10 (14%) patient 
did not experience ischemic 
events. Aspirin provides better clinical 
outcomes at age ≥ 65 years by reducing 
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Table III. Cross Tabulation Between 











aspirin 80 mg 6 (9%) 31 (45%) 37 
(54%) 
40-44 y.o - 1 (1%) 1 (1%) 
45-49 y.o - 1 (1%) 1 (1%) 
50-54 y.o 1 (1%) 2 (3%) 3 (4%) 
55-59 y.o 2 (3%) 5 (7%) 7 (10%) 
60-64 y.o 1 (1%) 6 (9%) 7 (10%) 
65-69 y.o - 10 (14%) 10 (14%) 
70-74 y.o 1 (1%) 3 (4%) 4 (6%) 
≥ 75 y.o 1 (1%) 3 (4%) 4 (6%) 
clopidogrel 
75 mg 
-     
40-44 y.o - 2 (3%) 2 (3%) 
45-49 y.o - 1 (1%) 1 (1%) 
50-54 y.o - 1 (1%) 1 (1%) 
55-59 y.o - 1 (1%) 1 (1%) 
60-64 y.o - 4 ( 4 
65-69 y.o - 1 (1%) 1 (1%) 
70-74 y.o - 1 (1%) 1 (1%) 
≥ 75 y.o - 1 (1%) 1 (1%) 
65-69 y.o - 2 (3%) 2 (3%) 
aspirin 80 mg 
+ clopidogrel 
75 mg 
2 (3%) 12 (17%) 14 
(20%) 
45-49 y.o 1 (1%) 2 (3%) 3 (4%) 
50-54 y.o 1 (1%) 1 (1%) 2 (3%) 
60-64 y.o - 2 (3%) 2 (3%) 
65-69 y.o - 4 (6%) 4 (6%) 
70-74 y.o - 2 (3%) 2 (3%) 
35-39 y.o - 1 (1%) 1 (1%) 




- 4 (6%) 4 (6%) 
55-59 y.o - 1 (1%) 1 (1%) 
60-64 y.o - 1 (1%) 1 (1%) 
70-74 y.o - 1 (1%) 1 (1%) 
≥ 75 y.o - 1 (1%) 1 (1%) 
Total 8 (12%) 61 (88%) 69 
(100%) 
  
Table IV. Cross Tabulation Between 
Antiplatelet, Comorbid 
conditions and Ischemic Events 
 
 Antiplatelet Therapy 








aspirin 80 mg 6 (9%) 31 
(45%) 
37 (54%) 
DCFC + HT + DM  1 (1%) - 1 (1%) 
Moderate AF + DCFC  - 1 (1%) 1 (1%) 
CKD + DM 1 (1%) - 1 (1%) 
CVA + HT + DM 
+ dyslipidemia 
- 1 (1%) 1 (1%) 
DCFC + HT + 
dyslipidemia 
- 1 (1%) 1 (1%) 
DM - 2 (3%) 2 (3%) 
DM + CKD + DCFC - 1 (1%) 1 (1%) 
DM + DCFC 2 (3%) 2 (3%) 4 (6%) 
DM + hyperglycemia + 
HT  
- 1 (1%) 1 (1%) 
DM + HT 2 (3%) 2 (3%) 4 (6%) 
DM + HT + DCFC 1 (1%) 1 (1%) 2 (3%) 
HT - 4 (6%) 4 (6%) 
HT + AV block - 1 (1%) 1 (1%) 
HT + CKD - 1 (1%) 1 (1%) 
HT + DCFC - 3 (4%) 3 (4%) 
HT + DCFC + CKD - 1 (1%) 1 (1%) 
HT + dyslipidemia 1 (1%) 2 (3%) 3 (4%) 
HT + DM + DCFC - 1 (1%) 1 (1%) 
HT + DM + dyslipidemia - 1 (1%) 1 (1%) 
without comorbidities - 3 (4%) 3 (4%) 
clopidogrel 75 mg -     
CKD - 1 (1%) 1 (1%) 
DM - 1 (1%) 1 (1%) 
DM + HT + DCFC - 2 ( 2 %) 2 ( 2 %) 
HT - 2 ( 2 %) 2 ( 2 %) 
HT + dyslipidemia - 1 (1%) 1 (1%) 
HT + dyslipidemia + 
hyperuricemia 
- 1 (1%) 1 (1%) 
HT + hyperuricemia + 
gastritis 
- 1 (1%) 1 (1%) 
without comorbidities - 1 (1%) 1 (1%) 
DM + CKD + CVA + 
dyslipidemia + post MF 
- 1 (1%) 1 (1%) 
DM + HT - 1 (1%) 1 (1%) 
HT + DCFC - 1 (1%) 1 (1%) 
HT + DCFC + CVA - 1 (1%) 1 (1%) 
aspirin 80 mg + 
clopidogrel 75 mg 
2 (3%) 12 
(17%) 
14 (20%) 
CVA + HT + DCFC - 1 (1%) 1 (1%) 
CVA infarction + 
hyperuricemia 
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 Antiplatelet Therapy 








DM + CVA + AF post 1 (1%) - 1 (1%) 
DM + HT + 
dyslipidemia  
- 1 (1%) 1 (1%) 
HT - 1 (1%) 1 (1%) 
HT + CVA - 1 (1%) 1 (1%) 
HT + CVA + 
dyspepsia 
- 1 (1%) 1 (1%) 
HT + DCFC + 
dyslipidemia 
- 1 (1%) 1 (1%) 
HT + dysilipidemia + 
DCFC 
1 (1%) - 1 (1%) 
without comorbidities - 5 (7%) 5 (7%) 
aspirin 80 
mg switch clopidogrel 75 
mg 
- 4 (6%) 4 (6%) 
DCFC - 1 (1%) 1 (1%) 
DM - 1 (1%) 1 (1%) 
HT + CVA + 
dyslipidemia + DM 
- 1 (1%) 1 (1%) 
HT + dyslipidemia - 1 (1%) 1 (1%) 




The profile of antiplatelet, comorbid 
conditions, and ischemic events seen 
in Table IV. Hypertension, Diabetes 
Melllitus, and Dyslipidemia is the most 
common comorbid conditions in patients 
with ischemic events.  
High blood pressure is a major risk 
factor for coronary heart disease. A higher 
systolic pressure increases myocardial 
oxygen demand and the development of 
coronary atherosclerosis. This process 
results in angina pectoris (Weber T, Lang 
I, Zweiker R, et al 2016).  Framingham's 
research also found a relationship between 
CHD and diastolic blood pressure. The 
incidence of myocardial infarction is 2x 
greater in the blood pressure group at 90-
104 mmHg compared to 85 mmHg 
diastolic blood pressure, whereas in s 
ystolic blood pressure 105 mmHg 4x is 
greater (Nelwan EJ, Widjajanto E, 
Andarini S, et al¸ 2016). In Diabetes 
Mellitus patient, high blood glucose level 
can increase blood viscosity that can 
increase blood pressure and also can 
damage endothelium of blood vessel 
which can lead to atherosclerosis (Reiner 
et al, 2011). Dyslipidaemia also took place 
in ischemic events. It can be worsen 
coronary heart disease by increased plaque 
formation in the blood vessel. 
Table V.  Results of the Naranjo 
scale Algorithm score for 
adverse drug reactions 
 










Dyspepsia 3 Possible 
ADR Bruised 





















Incidence of bleeding in the use of 
antiplatelet is one of the side effects that 
occur. Bleeding that occurs can be known 
by signs such as bleeding in the gums, 
nasal bleeding, and the occurrence of 
bruises. In addition, antiplatelet therapy 
also causes gastrointestinal bleeding 
especially in elderly patients (Yasuda H, 
2015). From 69 patients, side 
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these 4 patients, 3 of 
them caused gastrointestinal disorders and 
1 patient had  gums bleeding.  
After calculating the score using 
the naranjo scale on the occurrence 
of side effects on these 4 patients, it was 
found that 3 patients who 
had gastrointestinal disorders received a 
score of 3 and 1 patient who had bleeding 
gums got a score of 4 which is possible 
adverse drug reaction (ADR). To reduce 
the likelihood of ADR occurrence in the 4 
patients above, the actions taken were that 
patient  received PPI therapy and 
switched aspirin 80 mg to 75 mg 
clopidogrel, patient 2  who was using a 
combination of antiplatelet during the 
bleeding period changed to 
a single antiplatelet , patient 3 and 4 




Ischemic events are higher in 
patients using Aspirin 80 mg with 
comorbid conditions: hypertension, 
dyslipidemia, and Diabetes Mellitus. The 
rate of adverse drug reaction is quite small, 
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